ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs MXN
16.9766
0.19%
Brent Oil
83.63
0.11%
Bitcoin
59,426.86
2.04%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Entera Bio Ltd (ENTX)

  7. Entera Bio Ltd (ENTX) Noticias

ENTX Entera Bio Ltd

2.09
0.09 (4.50%)
Fuera de horario
Última actualización: 15:30:00
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Entera Bio Ltd ENTX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.09 4.50% 2.09 15:30:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.05 1.93 2.12 2.09 2.00
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
08/4/202407:30GLOBEEntera Bio Announces Publication of Oral PTH(1-34) Peptide..
26/3/202407:30GLOBEEntera Bio Announces Key Regulatory Milestone for Oral..
20/3/202407:00GLOBEEntera Bio Announces Robust Pharmacokinetic Data for..
08/3/202415:25EDGAR2Form S-8 - Securities to be offered to employees in employee..
08/3/202415:12EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/3/202415:10EDGAR2Form 8-K - Current report
08/3/202415:05GLOBEEntera Bio Announces Full Year 2023 Financial Results and..
04/3/202407:30EDGAR2Form 8-K - Current report
04/3/202407:30GLOBEEntera Bio Regains Compliance with Nasdaq Minimum Bid Price..
15/2/202416:10EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
14/2/202405:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
02/2/202415:19EDGAR2Form 8-K - Current report
02/2/202415:17EDGAR2Form S-3 - Registration statement under Securities Act of..
30/1/202407:30GLOBEEntera Bio to Present at the Oppenheimer 34th Annual..
16/1/202407:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/1/202417:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202417:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202407:00EDGAR2Form 8-K - Current report
27/12/202307:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/12/202307:00EDGAR2Form 8-K - Current report
26/12/202307:00GLOBEEntera Bio Announces Closing of Private Placement - Extends..
29/11/202307:30GLOBEInterim Results from Ongoing Clinical Study Confirm EB613..
14/11/202306:30GLOBEEntera Bio Reports Q3 2023 Financial Results, Highlights..
09/11/202313:30GLOBEEntera Bio Reports Key Milestone Relating to Oral PTH (1-34)..
16/10/202307:00GLOBEEntera Bio Reports Rapid Pharmacodynamic (PD) Response and..
14/9/202316:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/9/202316:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/9/202315:05EDGAR2Form 8-K - Current report
12/9/202307:30GLOBEEntera Bio Announces Collaboration with OPKO Biologics to..
05/9/202307:00GLOBEEntera Bio to Participate in Upcoming Investor Conferences
24/8/202307:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/8/202307:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/8/202308:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202307:30GLOBEEntera Bio to Present Two Abstracts on its First-in-Class,..
15/8/202315:10EDGAR2Form DEF 14A - Other definitive proxy statements
11/8/202315:19EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202315:16EDGAR2Form 8-K - Current report
11/8/202315:05GLOBEEntera Bio Announces Q2 2023 Financial Results and Corporate..
30/6/202315:06EDGAR2Form 8-K - Current report
07/6/202306:30GLOBEEntera Bio Adds Sanofi Commercial Leader, Haya Taitel to its..
05/5/202315:05GLOBEEntera Bio Announces Q1 2023 Financial Results and Corporate..
03/5/202308:34GLOBEEntera’s Oral Delivery of GLP-2 Pre-Clinical Data to be..

Su Consulta Reciente

NASDAQ
ENTX
Entera Bio
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados